Healthcare Moves: A Monthly Summary of Hires and Layoffs
Here is a selection of recent executive hires, departures and layoffs occurring across the healthcare industry.
Here is a selection of recent executive hires, departures and layoffs occurring across the healthcare industry.
DNA sequencing power house Illumina sued liquid biopsy company Guardant Health, whose founders used to work for Illumina, claiming the two stole information from Illumina to file patents for Guardant. Illumina alleges that one of the executives misappropriated confidential information while he was still on Illumina's payroll.
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
What draws investors to healthcare startups? In this series in the runup to MedCity INVEST in Chicago, we'll highlight these perspectives. If you're a startup in pharma tech, value-based care and care coordination, diagnostics or remote patient monitoring/smart devices, apply to our Pitch Perfect contest today.
Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.
In a phone interview, Guardant Health CEO Helmy Eltoukhy said he expected the approval to encourage coverage by those payers still on the sidelines.
The study, by US and Korean researchers, found Guardant360's detection of MSI-H/dMMR "highly concordant" with that of standard tissue biopsy, including in a subset of gastric cancer patients who responded to immunotherapy.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The South San Francisco company intends to use the funding to launch its pivotal trial for its blood-based colorectal cancer screening and submit its test for parallel review for CMS coverage.
An investment analyst wrote that physicians see the results as potentially ushering in a "liquid-first" testing paradigm, but the liquid biopsy market is likely to include several or even more than a dozen major players.
Judy Smythe, Bardia Akbari and Niv Caviar have been named as the company's chief operating officer, senior vice president of clinical operations and chief financial officer, respectively.
The company, which has already raised more than $500 million in venture capital funding, would trade on the NASDAQ under the ticker symbol "GH."
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Investment could be called frothy, but hasn't reached bubble territory yet, SVB report author says.
In a new analysis, Accenture dives deeper into digital health funding. The assessment includes a prediction that annual investment in digital health startups will reach $7 billion by the end of 2017.
A family member's liquid biopsy test, gene testing and a journey into coverage decisions and clinical guidelines reveal how difficult the reimbursement path is for these emerging technologies.
Guardant Health has unveiled an ambitious five-year plan to sequence tumor DNA from one million cancer patients. Dubbed "Guardant 1 million," the push will be financed with $360 million in new financing from a broad syndicate of investors.
The Redwood City, Calif.-based company has raised nearly $100 million in Series D financing led by OrbiMed Advisors.